JBIO Jade Biosciences, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1798749 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-29.9%
TTM EPS YoY44.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-51.4%
ROA-47.4%
ROIC (approx.)-55.4%
Asset turnover—
Leverage & solvency
Liabilities / assets6.4%
Debt / equity0.00x
Current ratio16.03x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.80x
Accruals ratio-9.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $93.12M | $53.19M | $64.22M | $38.62M | $14.99M |
| SG&A expense | $20.42M | $21.41M | $17.19M | $14.62M | $8.04M |
| Operating income | -$113.54M | -$74.60M | -$81.41M | -$53.24M | -$23.02M |
| Pretax income | -$127.35M | -$69.57M | -$75.47M | -$51.49M | -$22.96M |
| Income tax | $58,000 | $55,000 | $56,000 | $25,000 | $3,000 |
| Net income | -$127.41M | -$69.63M | -$75.52M | -$51.51M | -$22.96M |
| EBITDA | -$113.52M | -$74.31M | -$81.31M | -$53.17M | -$23.01M |
| EPS (basic) | -3.19 | -2.44 | -2.87 | -2.10 | -1.87 |
| EPS (diluted) | -3.19 | -2.44 | -2.87 | -2.10 | -1.87 |
| Weighted avg. shares (diluted) | 31.36M | 28.58M | 26.33M | 24.47M | 12.29M |
| Balance sheet | |||||
| Cash & equivalents | $88.44M | $69.39M | $23.49M | $22.40M | $54.20M |
| Short-term investments | $247.72M | $0 | $98.95M | $106.82M | $113.18M |
| Current assets | $348.82M | $69.65M | $124.23M | $131.50M | $174.33M |
| PP&E, net | $170,000 | $0 | $288,000 | $242,000 | $186,000 |
| Total assets | $349.78M | $72.80M | $127.42M | $135.30M | $175.36M |
| Current liabilities | $16.54M | $12.00M | $17.64M | $7.78M | $2.55M |
| Total liabilities | $17.26M | $119.60M | $17.96M | $8.56M | $2.94M |
| Shareholders' equity | $332.52M | -$46.80M | $109.46M | $126.74M | $172.42M |
| Shares outstanding | 49.32M | 3.67M | 27.76M | 24.72M | 24.41M |
| Cash flow statement | |||||
| Operating cash flow | -$94.69M | -$71.20M | -$56.78M | -$39.12M | -$27.40M |
| Capital expenditure | $196,000 | — | $142,000 | $195,000 | $181,000 |
| Free cash flow | -$94.89M | — | -$56.92M | -$39.32M | -$27.58M |
| Investing cash flow | -$247.01M | $56.03M | $11.88M | $6.93M | -$113.43M |
| Financing cash flow | $360.77M | $25.43M | $46.00M | $396,000 | $190.46M |
| Depreciation & amortization | $26,000 | $282,000 | $96,000 | $68,000 | $15,000 |
| Stock-based compensation | $20.01M | $11.31M | $11.91M | $5.48M | $2.04M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.